IITRI now offers an improved bleomycin (BLM) induced pulmonary fibrosis mouse model that can recapitulate many of the complex profibrotic responses that are also observed in the lungs of those suffering from idiopathic pulmonary fibrosis (IPF) and perhaps COVID-19 patients as well. Data from previous coronavirus infections, as well as early analysis from patients with COVID-19 on discharge from hospital, suggest there could be substantial fibrotic consequences following the SARS-CoV-2 infection.
It is generally accepted that the current BLM mouse model needs to be improved to provide a more progressive fibrosis as is thought to occur in humans. Our new approach is a non-invasive intra-bronchial instillation to induce pulmonary fibrosis in one side of lung only, allowing an increased BLM dose for more pulmonary fibrosis without killing animals.
Bleomycin-induced Pulmonary Fibrosis Model
Benefits of our model
– Bigger separation window between sham and BLM mice
– More consistent scale of pulmonary fibrosis in the BLM mice
– Generates a severe active fibrotic phase, mimicking acute exacerbation of IPF
|Species||Male C57BL/6 mice (8-12 weeks)|
|Study Duration||14 or 21 days|
Intra-bronchial unilateral administration of BLM for disease induction
|Endpoints||Body weight, lung weight, histopathology of the lungs, BAL cell counts, immunoassays|
IITRI provides IND-enabling vaccine programs, with over 30 years of experience conducting GLP-compliant toxicology studies. We support vaccine basic research through FDA approval programs for sponsors from government, biotech, academic, and pharma institutions.